01 March 2005
Bifenthrin activates homotypic aggregation in human T-cell lines.Nataly Hoffman, Van Tran, Anthony Daniyan, Olutosin Ojugbele, Stephen Pryor, Josephine Bonventre, Katherine Flynn, Benjamin Weeks
Med Sci Monit 2006; 12(3): BR87-94 :: ID: 447101
Background: Here, we addressed the concern that, despite the lack of overttoxicity, exposure to low levels of the common household pyrethroid pesticide, bifenthrin, could causeharm to the immune system. To do this, we measure the effect of bifenthrin on phytohemagglutinin (PHA)activation of homotypic aggregation in human T-cell lines. Material/Methods: The human CD4+ H9, and Jurkatcell lines and the human promonocyte U937 cell line, were exposed to varying concentrations of bifenthrin.Cell viability was determined using the AlmarBlue Toxicity Assay. Concentrations of bifenthrin whichdid not reduce cell viability were determined and these concentrations were tested for the effect ofbifenthrin on PHA-mediated homotypic aggregation. Blocking antibodies to ICAM and LFA-1 were used todisrupt aggregation and a nonspecific IgG was used as a control. Results: Bifenthrin was found to benontoxic at concentrations ranging from 10[sup]-4[/sup] to 10[sup]-13[/sup] M. Bifenthrin did not inhibit PHA induced cellaggregation in all cell lines tested. However, at 10[sup]-4[/sup] M, bifenthrin to form aggregates stimulatedhomotypic aggregation in the H9 and Jurkat T-cell lines. The bifenthrin-induced aggregate formation,like that seen with PHA, was blocked by treating the cells with antibodies to either LFA-1 or ICAM. Conclusions:The results here show that bifenthrin activates T-cell function by stimulating ICAM/LFA-1 mediated homotypicaggregation. This data suggests that exposure to bifenthrin, even at "acceptable" limits, can increasethe risk for and frequency of inflammatory responses and diseases such as asthma.
Keywords: Intercellular Adhesion Molecule-1 - immunology, U937 Cells, Time Factors, T-Lymphocytes - immunology, Pyrethrins - pharmacology, Phytohemagglutinins - pharmacology, Lymphocyte Function-Associated Antigen-1 - immunology, Jurkat Cells, Cell Aggregation - immunology, Insecticides - pharmacology, Hela Cells, Dose-Response Relationship, Drug, Cell Survival - drug effects, Antibodies, Monoclonal - metabolism
01 June 2023 : EditorialEditorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness
Med Sci Monit 2023; 29:e941209
08 Jun 2023 : Clinical ResearchRisk Factors for New Vertebral Compression Fracture After Percutaneous Vertebral Augmentation: A Retrospect...
Med Sci Monit In Press; DOI: 10.12659/MSM.940134
08 Jun 2023 : Clinical ResearchA Nomogram for Identifying HR+/Her2- Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted ...
Med Sci Monit In Press; DOI: 10.12659/MSM.940124
08 Jun 2023 : Clinical ResearchBurden of COVID-19 on Mental Health of Resident Doctors in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940208
08 Jun 2023 : Clinical ResearchRisk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: Th...
Med Sci Monit In Press; DOI: 10.12659/MSM.940251
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952